Abstract
The plant kingdom is a rich source of compounds with anticancer activities. Curcumin [1,7-bis(4-hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione] (1) is a secondary metabolite produced by rhizomes of Curcuma longa that has been used for centuries in traditional Medicine in Asia. Anticancer activity is one of the pharmacological properties of curcumin (1) that has been widely explored. Its targets include transcription factors, growth and angiogenesis regulators, apoptosis-related genes, adhesion-related molecules, and cellular signaling molecules. Some curcumin conjugates and metallocomplexes have been synthesized, characterized and evaluated for anticancer activity. In this mini-review, we discuss the mechanism of action by which curcumin (1) inhibits the progression of tumor growth and also the antiproliferative activity of curcumin conjugates and metallocomplexes on human cancer cells. The understanding of how these conjugates and metallocomplexes exert their anticancer activities is essential for future development of effective drugs.
Keywords: Curcumin, Curcumin conjugates and metallocomplexes, Cancer, Antiproliferative activity
Current Bioactive Compounds
Title: Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Volume: 4 Issue: 3
Author(s): Angelo de Fatima, Luzia V. Modolo, Ana Tereza M. Neres, Carmen V. Ferreira and Ana Carolina S. de Souza
Affiliation:
Keywords: Curcumin, Curcumin conjugates and metallocomplexes, Cancer, Antiproliferative activity
Abstract: The plant kingdom is a rich source of compounds with anticancer activities. Curcumin [1,7-bis(4-hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione] (1) is a secondary metabolite produced by rhizomes of Curcuma longa that has been used for centuries in traditional Medicine in Asia. Anticancer activity is one of the pharmacological properties of curcumin (1) that has been widely explored. Its targets include transcription factors, growth and angiogenesis regulators, apoptosis-related genes, adhesion-related molecules, and cellular signaling molecules. Some curcumin conjugates and metallocomplexes have been synthesized, characterized and evaluated for anticancer activity. In this mini-review, we discuss the mechanism of action by which curcumin (1) inhibits the progression of tumor growth and also the antiproliferative activity of curcumin conjugates and metallocomplexes on human cancer cells. The understanding of how these conjugates and metallocomplexes exert their anticancer activities is essential for future development of effective drugs.
Export Options
About this article
Cite this article as:
de Fatima Angelo, Modolo V. Luzia, Neres M. Ana Tereza, Ferreira V. Carmen and de Souza S. Ana Carolina, Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review, Current Bioactive Compounds 2008; 4 (3) . https://dx.doi.org/10.2174/157340708786305934
DOI https://dx.doi.org/10.2174/157340708786305934 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry The Role of Vitamin D and Sunlight Incidence in Cancer
Anti-Cancer Agents in Medicinal Chemistry Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction
Current Neuropharmacology Synthetic Nanocarriers for Intracellular Protein Delivery
Current Drug Metabolism Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Assessment of a Synthetic Steroid and Flutamide on Dopamine, GSH and H<sub>2</sub>O<sub>2</sub> Levels in Rat Brain in Presence of Fructose
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease
Current Chemical Biology High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Natural Products as Anticancer Agents
Current Drug Targets The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Engineered Polymer Nanoplatforms for Targeted Tumor Cells and Controlled Release Cargos to Enhance Cancer Treatment
Current Medicinal Chemistry Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets